National Benicar Lawsuit Attorneys

Contact Golomb & Honik, P.C. at (215) 278-4449

Benicar was developed in 1995 for the treatment of hypertension or high blood pressure and was approved for use by the FDA in 2002. From 2002 to 2008, pharmaceutical maker Daiichi Sankyo spent nearly $1 billion promoting the product and making claims that their drug was safe and more effective than other hypertensive drugs on the market. Yet the use of this drug has now been linked to severe intestinal problems, chronic diarrhea, and a severe condition known as sprue-like enteropathy.

Our national dangerous drug lawsuit attorneys at Golomb & Honik, P.C. are currently investigating Benicar claims. If you or someone you love has been diagnosed with sprue-like enteropathy or other severe gastrointestinal problems after taking Benicar, call us at (215) 278-4449. We would be happy to review your case free of charge.

Severe Complications from Benicar

The U.S. Food and Drug Administration recently warned consumers in 2013 that the use of Benicar could cause severe gastrointestinal problems, including:

  • Villous Atrophy
  • Malnourishment
  • Dehydration
  • Chronic diarrhea
  • Malnutrition
  • Nausea
  • Vomiting
  • Abdominal pain
  • Sprue-like enteropathy
  • Weight loss
  • And more

What is Sprue-like Enteropathy?

The most serious gastrointestinal complication experienced by patients taking Benicar is sprue-like enteropathy. This severe GI disorder can cause serious symptoms, such as severe, chronic diarrhea, substantial weight loss, and malnutrition. To make matters worse, this condition may take years to develop and be diagnosed and is often mistaken for Celiac disease or gluten intolerance. By the time sprue-like enteropathy is diagnosed, patients are sick, malnourished, and often hospitalized.

Link Between Benicar & Sprue-like Enteropathy

Benicar has been marketed as Benicar, Benicar HCT, Azor, Tribenzor, and the generic name olmesartan medoxomil. In 2012, researchers from the Mayo Clinic uncovered the link between Benicar and sprue-like enteropathy. They found that over a 3-year period, at least 22 patients taking Benicar were admitted with celiac disease symptoms-yet further testing did not support this diagnosis.

When those patients were removed from their Benicar, however, the symptoms ceased. Those patients who reported suffering from Celiac like symptoms had diarrhea for up to 53 months and had lost between 5 and 110 pounds from GI complications. They had also experienced rounds of nausea, vomiting, and abdominal pain.

Months later, scientists at the AmericanCollege of Gastroenterology found that the active ingredient in Benicar, olmesartan, was also linked to sprue-like enteropathy and debilitating GI symptoms in over 40 patients. In 2013, the FDA required Daiichi Sankyo to update their labels to reflect these findings and warned the public of Benicar’s dangers.

We Can Help with Your Benicar Lawsuit - Call (215) 278-4449

In 2014, Benicar lawsuits began to be filed in the New Jersey state courts citing failure to warn and other negligence by Daiichi Sankyo. The first lawsuit was filed on behalf of a patient who was forced to spend 100 days hospitalized because of his GI issues. He suffered cataracts, compression fractures, and severe malnutrition and must now be fed through a feeding tube. His lawsuit alleges that the company continued to put consumers at risk by not adequately warning of the dangers associated with using their drug. It also alleges that Daiichi Sankyo failed to adequately test their product before introducing it to the public.

You have a right to seek justice if you or someone you love has been diagnosed with sprue-like enteropathy or experienced severe gastrointestinal complications after taking Benicar. Drug companies that routinely put profits before people should pay for their negligence-and their unscrupulous behavior.

Call us at (215) 278-4449 or contact us online to request your free and confidential case evaluation!

Over $2 Billion Won in Verdicts and Settlements

  • $410,000,000 Bank of America Class Action
  • $358,000,000 Benicar Drug Settlement
  • $250,000,000 Granuflo Medical Device Settlement
  • $162,000,000 JP Morgan Class Action
  • $137,500,000 Citizen Bank Class Action
  • $130,000,000 Against Credit Card Companies
  • $90,000,000 PNC Bank Class Action
  • $70,000,000 TD Bank Class Action
  • More Than $65,000,000 On Behalf of Attorneys General
  • $62,500,000 TD Bank Class Action